At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 801 enrolled
Drug / intervention
ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live) +3 morebiological
Likely dose
ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live) 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Administration of Frozen Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to Healthy Children at 4 to 6 Years of Age
In Brief
A Phase 3 clinical trial evaluating ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live), Comparator: M-M-R II, and 2 other interventions for Measles and 3 related conditions. Completed, enrolled 801 participants.
Detailed Summary
The study was conducted to determine if ProQuad may be used in place of the second dose of M-M-R II routinely given to children 4 to 6 years old who were previously immunized with M-M-R II and Varivax.
Study Details
Timeline
Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2000
Primary CompletionMay 2002
Study CompletionMay 2003
First PostedSep 2009
TodayJul 2026
First PostedSep 28, 2009
Enrollment StartAug 1, 2000
Primary CompletionMay 1, 2002
Study CompletionMay 1, 2003
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.8 years ago
Interventions
ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)biological
A Single 0.5 mL subcutaneous injection at Day 1
Comparator: M-M-R IIbiological
A Single 0.5 mL subcutaneous injection at Day 1
Comparator: Varivaxbiological
A Single 0.5 mL subcutaneous injection at Day 1
Comparator: Placebobiological
A Single 0.5 mL subcutaneous placebo injection at Day 1